There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
ORGANIZATION
Discuss Cost Effectiveness Assessment, Disclosure Ratios Separately: FPMAJ
Japan’s cost-effectiveness assessment (CEA) scheme introduced in April not only targets products granted launch premiums but also cuts into non-granted ones depending on the ratio of manufacturing cost disclosures. The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) reiterated its…
To read the full story
Related Article
- Generic Share Hits Plateau after Reaching 70%: FPMAJ Pharmacy Survey
June 17, 2019
- Japan to Roll Out Cost-Effectiveness Assessment Scheme in April
February 21, 2019
- MHLW Unveils Outline of Cost-Effective Assessment Scheme: Chuikyo
January 24, 2019
ORGANIZATION
- Single-Wholesaler Distribution Should Be Redressed from Stable Supply Standpoint: JMA Official
August 4, 2022
- JPWA Chief Questions Patient Benefits of Single-Wholesaler Distribution
August 1, 2022
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
- JPMA Delays Announcement of Drug Pricing Proposal
July 27, 2022
- JPMA Hails New Expert Panel, Plans to Raise “Drug Loss” Issue: Director General
July 25, 2022
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…